Inflammatix Collaborates with University of Nebraska Medical Center to Support Rapid Response to the Hantavirus Outbreak Using TriVerity®
Host-response enables rapid assessment of infection type and risk of deterioration in high-consequence infectious disease setting.
Sunnyvale, CA, June 16, 2026 — Inflammatix, a leader in precision diagnostics for acute infection, today announced its collaboration with the University of Nebraska Medical Center and the National Quarantine Unit to support the response to the hantavirus outbreak using its TriVerity® test.
Hantavirus presents a significant clinical challenge, often beginning with non-specific symptoms that resemble common viral illnesses but can rapidly progress to severe respiratory failure. Early identification of patients at risk of deterioration remains difficult using traditional diagnostic approaches, which rely on pathogen detection that may not be immediately available or actionable in acute care settings. However, as with many viruses with pandemic potential, tests that specifically detect hantaviruses are either not widely distributed (serology tests) or still under development (such as PCR tests).
TriVerity® takes a fundamentally different approach by measuring the body’s immune response through host mRNA, providing clinicians with three actionable insights from a single blood sample: likelihood of bacterial infection, likelihood of viral infection, and the likelihood of requiring ICU-level care within seven days. The test runs in approximately 30 minutes and is intended for clinical use in emergency departments for patients with suspected infection or sepsis, and at least one vital sign abnormal.
